Stefan Kleiser joined the Entrepreneur Fellowship program to work on translating a novel oximeter to clinical use. Based on a highly precise research tissue oximeter, he and his team developed a medical device improving intensive care by avoiding oxygen undersupply and brain damage. The translation of OxyPrem has be focused on user needs and industrialized manufacturing, in close linkage and cooperation with later customers. To date, the team has developed a product that is about to be CE-certified. Oxyprem’s vision is to contribute to a decrease in child mortality and severe life-long brain damage in survivors.
Oxyprem is currently supported by Uniscientia foundation, Venture Kick, and Wyss Zurich. They received the CE-certification for their product in summer 2019.
Affiliation: Prof. Dr. Martin Wolf
Start date: 02/2018
Stefan Kleiser co-founded the UZH Spin-off OxyPrem AG in 2018
OxyPrem enters WYSS Zurich in 2019
OxyPrem was awarded the Seal of Excellence by the European Union's Accelerator program (SME Instrument phase II) in 2020
OxyPrem has obtained CHF 2.2 milion from SERI-funded EIC Accelerator grant in 2022
OxyPrem wins 2nd place at SWISS EXCELLENCE AWARD in 2022